Streetbeat News

Regulatory

AVGR

Avinger has received FDA 510(k) clearance for its next-generation Pantheris LV image-guided atherectomy system, designed for the treatment of peripheral artery disease (PAD).

Portfolio Pulse from Benzinga Newsdesk

June 07, 2023 | 12:09 pm

SPY

US Treasury Secretary Yellen stated that there is a path to reducing inflation while maintaining a strong labor market, and noted signs of easing in the labor market.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2023 | 12:06 pm

OCUL

Ocular Therapeutix has completed enrollment for the HELIOS clinical trial of OTX-TKI, a treatment for diabetic retinopathy. This marks a significant milestone for the company's development of the drug.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2023 | 12:04 pm

HCTI

Healthcare Triangle (HCTI) has received a Nasdaq delisting notice and has submitted a request for a hearing to appeal the determination on June 5, 2023.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2023 | 12:04 pm

FSR

Fisker Inc (NYSE:FSR) has agreed to sell emission credits to a major automaker ahead of its first US delivery of the all-electric Fisker Ocean SUV in June. The company expects to generate the maximum allowable emission credits per vehicle, helping other automakers avoid non-compliance penalties.

Portfolio Pulse from Anan Ashraf

June 07, 2023 | 11:32 am

ALGS

Aligos Therapeutics will present data on its liver disease programs at the European Association for the Study of the Liver (EASL) Congress 2023 from June 21-24.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2023 | 11:31 am

TNXP

Tonix Pharmaceuticals announced data presentations involving TNX-1500 for the prevention of rejection in kidney and heart allograft transplantation in animal models. TNX-1500 is expected to enter Phase 1 trial in Q3 2023.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2023 | 11:09 am

META

The Wall Street Journal reported that Meta's Instagram has been connecting a vast pedophile network, according to investigations by WSJ, researchers at Stanford University, and the University of Massachusetts Amherst.

Portfolio Pulse from Charles Gross

June 07, 2023 | 11:08 am

VTYX

Ventyx Biosciences has completed enrollment for its Phase 2 trials of VTX002 in ulcerative colitis and VTX958 in plaque psoriasis. Topline data for both trials are expected in early Q4 and Q4 2023, respectively.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2023 | 11:06 am

VTYX

Ventyx Biosciences (NASDAQ:VTYX) has completed patient enrollment for its Phase 2 trials of VTX002 in ulcerative colitis and VTX958 in plaque psoriasis.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2023 | 11:04 am